The director of the Center for Clinical Ethics at Yale New Haven Health provided insights on newly published guidelines for functional seizures, stressing the reasons for systemic psychiatric assessment and careful seizure characterization. [WATCH TIME: 3 minutes]
A duo of experts from CureDuchenne discussed how the inclusion of Duchenne muscular dystrophy on the Recommended Uniform Screening Panel can enable earlier diagnosis and inform decision-making in a rapidly evolving therapeutic landscape. [WATCH TIME: 7 minutes]
The associate chief medical officer at Michigan State University highlighted advances in neuromuscular disease, emerging therapeutic strategies, and the growing role of patient-reported outcomes at AANEM 2025. [WATCH TIME: 2 minutes]
A forward-looking discussion on cardiac monitoring strategies, real-world data, and how vamorolone may apply across Duchenne and Becker muscular dystrophy.
The chief medical officer at Xenon Pharmaceuticals provided clinical insights on promising long-term, phase 2 data testing azetukalner, a first-in-class Kv7 channel opener, in patients with focal onset seizures. [WATCH TIME: 4 minutes]
The consultant neurologist at the National Neuroscience Institute discussed how artificial intelligence, biomarker development, and drug repurposing can help improve patient care in ALS. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending January 24, 2025. [WATCH TIME: 4 minutes]
Pediatric specialists stressed that the future of epilepsy care may involve embedding behavioral health clinicians in specialty clinics to identify and treat depression early, improve quality of life, and potentially reduce seizure burden. [WATCH TIME: 3 MINUTES]
The speakers review several emerging therapies under investigation for Parkinson’s disease, including gene therapy, stem cell transplantation, and antibody treatments targeting alpha-synuclein. These advances, along with new symptomatic and disease-modifying approaches, highlight the rapidly evolving treatment landscape and growing hope for improved outcomes for patients.
The speakers discuss IPX203, an extended-release carbidopa/levodopa formulation that provides more continuous levodopa delivery through a combination of immediate and sustained intestinal release. In the RISE-PD study, IPX203 increased “on” time, reduced “off” time and dyskinesia, and required fewer daily doses compared with immediate-release carbidopa/levodopa.
The professor of geriatrics and gerontology at the University of Wisconsin shared insights on prescribing the autoinjector formulation of lecanemab for patients living with Alzheimer disease. [WATCH TIME: 5 minutes]
Explore the importance of collaborative treatment approaches for managing epilepsy, emphasizing open communication between families and healthcare providers.
Parents navigate the complexities of genetic testing and Dravet syndrome, sharing insights on the importance of timely and informed medical support.
Joseph Sullivan, MD, discussed the importance of genetic testing and documenting findings to guide treatment and support smooth transitions from pediatric to adult care.
The senior director at the Banner Alzheimer's Institute talked about findings from the ancillary analyses of the US POINTER Study and the importance of strong recruitment efforts. [WATCH TIME: 5 minutes]
The head of search and evaluation at the Alzheimer's Drug Discovery Foundation discussed the evolving role of biomarkers for diagnosis and the progress of targeted therapies in Alzheimer disease. [WATCH TIME: 5 minutes]
In this segment, Wittlieb-Leber examines how vamorolone trials address long-standing questions about steroid exposure, cardiac risk, and meaningful cardiac endpoints in Duchenne.
The chief operating officer at Linus Health talked about how brief, digitally administered cognitive assessments enable scalable, earlier identification of cognitive impairment. [WATCH TIME: 4 minutes]
Pediatrics specialists discussed approaches to assessing depressive symptoms that may overlook key risk factors, highlighting the need for improved self-report measures, developmentally appropriate tools, and more precise symptom characterization. [WATCH TIME: 3 MINUTES]
The director at the National Center of Neurology and Psychiatry discussed how biomarker-driven diagnostics and antibody therapies targeting amyloid pathology may be reshaping Alzheimer disease management. [WATCH TIME: 4 minutes]
Pediatrics specialists discussed key methodological limitations of a recently published study, including variability across sites, reliance on caregiver-report measures, and the lack of developmentally appropriate tools for assessing depression in youth with intellectual disabilities. [WATCH TIME: 4 MINUTES]
Pediatric specialists reflected on the challenges and gaps in assessing depressive and anxiety symptoms among youth with epilepsy, emphasizing that patients with lower IQs are often excluded from research and clinical screening. [WATCH TIME: 3 MINUTES]
Neurology News Network for the week ending January 17, 2025. [WATCH TIME: 4 minutes]
Pediatric specialists reflected on the goal and findings of the study, describing the elevated prevalence of depressive symptoms among youth with epilepsy and highlighting temporal lobe epilepsy as a particularly high-risk subgroup. [WATCH TIME: 2 MINUTES]
The speakers review results from the TEMPO 1, 2, and 3 trials demonstrating that tavapadon improves motor symptoms as both monotherapy and adjunctive therapy in Parkinson’s disease. The drug may increase “on” time, reduce “off” time and dyskinesia, and potentially lessen the need for higher levodopa doses that contribute to motor fluctuations.
A panelist discusses how tavapadon’s D1/D5 receptor selectivity may offer potential benefits such as improved motor symptom control with a reduced risk of adverse effects commonly associated with traditional dopamine agonists.
In this segment, the physicians emphasize the importance of multidisciplinary care in managing the complex, lifelong needs of patients with NF1. One physician describes how comprehensive NF programs rely on coordinated input from neurology, ophthalmology, orthopedics, pulmonology, urology, endocrinology, dermatology, nephrology, neurosurgery, and psychosocial specialists to address the diverse medical and cognitive challenges associated with the condition. They highlight the essential role of neuropsychology, noting that many patients require ongoing assessment, educational support, and accommodations—services that are often harder to access in adulthood. The discussion then shifts to emerging treatments for plexiform neurofibromas. While MEK inhibitors remain the current standard, ongoing research is exploring combination therapies and novel agents with lower toxicity to reduce long-term treatment burdens. Finally, the physicians stress the need for proactive conversations about fertility, pregnancy safety, and “drug vacations” for young adults hoping to start families. They underscore the importance of genetic counseling and careful planning to balance treatment efficacy with reproductive goals.
At CTAD 2025, the director of Banner Alzheimer’s Institute discussed emerging epidemiologic and translational evidence suggesting that certain vaccines may confer protection against dementia. [WATCH TIME: 6 minutes]
The associate professor at The University of Tokyo talked about how lifestyle-focused multidomain interventions, including exercise, sleep, and nutrition, may improve cognitive function. [WATCH TIME: 4 minutes]
Genetic testing plays a crucial role in diagnosing Dravet syndrome early, guiding treatment plans, and improving patient outcomes.
